Infinity Announces Enrollment Of 120th Patient In Phase 2 DYNAMO™ Study Evaluating Duvelisib In Indolent Non-Hodgkin Lymphoma

By: via Benzinga
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that the 120th patient has been enrolled in DYNAMO™, a Phase 2 study in ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.